Evaluation of immune-enhancing effects of ibuprofen in an immunodeficiency model

J. L. Jorizzo, R. M. Goldblum, J. C. Daniels, Y. Ichikawa, M. P. Langford, K. M. Fagan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Three children and one adult with chronic mucocutaneous candidosis with documented deficient cellular immunity to Candida antigen were evaluated as a model to study the specific cellular immune-enhancing potential of the prostaglandin synthetase inhibitor ibuprofen. Oral ibuprofen failed to have any consistent effect during sequential 4-week on and off cycles on the following parameters: delayed hypersensitivity skin testing; lymphocyte transformation to Candida antigen; T-cell subsets as determined by monoclonal antibody techniques; production of human immune interferon in response to staphylococcal enterotoxin A (SEA). Two patients showed a trend toward enhanced lymphocyte transformation to PHA while taking ibuprofen. In two patients who were studied 8-10 weeks after discontinuation of oral ketoconazole therapy, clinical recurrence of CMC was not prevented by oral ibuprofen therapy.

Original languageEnglish (US)
Pages (from-to)183-187
Number of pages5
JournalInternational Journal of Dermatology
Volume24
Issue number3
StatePublished - 1985

Fingerprint

Ibuprofen
Lymphocyte Activation
Candida
Chronic Mucocutaneous Candidiasis
Antigens
Prostaglandin Antagonists
Ketoconazole
Delayed Hypersensitivity
T-Lymphocyte Subsets
Prostaglandin-Endoperoxide Synthases
Cellular Immunity
Interferon-gamma
Monoclonal Antibodies
Recurrence
Skin
Therapeutics

ASJC Scopus subject areas

  • Dermatology

Cite this

Jorizzo, J. L., Goldblum, R. M., Daniels, J. C., Ichikawa, Y., Langford, M. P., & Fagan, K. M. (1985). Evaluation of immune-enhancing effects of ibuprofen in an immunodeficiency model. International Journal of Dermatology, 24(3), 183-187.

Evaluation of immune-enhancing effects of ibuprofen in an immunodeficiency model. / Jorizzo, J. L.; Goldblum, R. M.; Daniels, J. C.; Ichikawa, Y.; Langford, M. P.; Fagan, K. M.

In: International Journal of Dermatology, Vol. 24, No. 3, 1985, p. 183-187.

Research output: Contribution to journalArticle

Jorizzo, JL, Goldblum, RM, Daniels, JC, Ichikawa, Y, Langford, MP & Fagan, KM 1985, 'Evaluation of immune-enhancing effects of ibuprofen in an immunodeficiency model', International Journal of Dermatology, vol. 24, no. 3, pp. 183-187.
Jorizzo JL, Goldblum RM, Daniels JC, Ichikawa Y, Langford MP, Fagan KM. Evaluation of immune-enhancing effects of ibuprofen in an immunodeficiency model. International Journal of Dermatology. 1985;24(3):183-187.
Jorizzo, J. L. ; Goldblum, R. M. ; Daniels, J. C. ; Ichikawa, Y. ; Langford, M. P. ; Fagan, K. M. / Evaluation of immune-enhancing effects of ibuprofen in an immunodeficiency model. In: International Journal of Dermatology. 1985 ; Vol. 24, No. 3. pp. 183-187.
@article{343d97e913174512b46fcbd0e64336ee,
title = "Evaluation of immune-enhancing effects of ibuprofen in an immunodeficiency model",
abstract = "Three children and one adult with chronic mucocutaneous candidosis with documented deficient cellular immunity to Candida antigen were evaluated as a model to study the specific cellular immune-enhancing potential of the prostaglandin synthetase inhibitor ibuprofen. Oral ibuprofen failed to have any consistent effect during sequential 4-week on and off cycles on the following parameters: delayed hypersensitivity skin testing; lymphocyte transformation to Candida antigen; T-cell subsets as determined by monoclonal antibody techniques; production of human immune interferon in response to staphylococcal enterotoxin A (SEA). Two patients showed a trend toward enhanced lymphocyte transformation to PHA while taking ibuprofen. In two patients who were studied 8-10 weeks after discontinuation of oral ketoconazole therapy, clinical recurrence of CMC was not prevented by oral ibuprofen therapy.",
author = "Jorizzo, {J. L.} and Goldblum, {R. M.} and Daniels, {J. C.} and Y. Ichikawa and Langford, {M. P.} and Fagan, {K. M.}",
year = "1985",
language = "English (US)",
volume = "24",
pages = "183--187",
journal = "International Journal of Dermatology",
issn = "0011-9059",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Evaluation of immune-enhancing effects of ibuprofen in an immunodeficiency model

AU - Jorizzo, J. L.

AU - Goldblum, R. M.

AU - Daniels, J. C.

AU - Ichikawa, Y.

AU - Langford, M. P.

AU - Fagan, K. M.

PY - 1985

Y1 - 1985

N2 - Three children and one adult with chronic mucocutaneous candidosis with documented deficient cellular immunity to Candida antigen were evaluated as a model to study the specific cellular immune-enhancing potential of the prostaglandin synthetase inhibitor ibuprofen. Oral ibuprofen failed to have any consistent effect during sequential 4-week on and off cycles on the following parameters: delayed hypersensitivity skin testing; lymphocyte transformation to Candida antigen; T-cell subsets as determined by monoclonal antibody techniques; production of human immune interferon in response to staphylococcal enterotoxin A (SEA). Two patients showed a trend toward enhanced lymphocyte transformation to PHA while taking ibuprofen. In two patients who were studied 8-10 weeks after discontinuation of oral ketoconazole therapy, clinical recurrence of CMC was not prevented by oral ibuprofen therapy.

AB - Three children and one adult with chronic mucocutaneous candidosis with documented deficient cellular immunity to Candida antigen were evaluated as a model to study the specific cellular immune-enhancing potential of the prostaglandin synthetase inhibitor ibuprofen. Oral ibuprofen failed to have any consistent effect during sequential 4-week on and off cycles on the following parameters: delayed hypersensitivity skin testing; lymphocyte transformation to Candida antigen; T-cell subsets as determined by monoclonal antibody techniques; production of human immune interferon in response to staphylococcal enterotoxin A (SEA). Two patients showed a trend toward enhanced lymphocyte transformation to PHA while taking ibuprofen. In two patients who were studied 8-10 weeks after discontinuation of oral ketoconazole therapy, clinical recurrence of CMC was not prevented by oral ibuprofen therapy.

UR - http://www.scopus.com/inward/record.url?scp=0021920862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021920862&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 183

EP - 187

JO - International Journal of Dermatology

JF - International Journal of Dermatology

SN - 0011-9059

IS - 3

ER -